BFM
SLRN

Boothbay Fund Management’s ACELYRIN SLRN Stock Holding History

Boothbay Fund Management’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-74,000
Closed -$552K – 1903
2023
Q4 		$552K Buy
74,000
+46,400
+168% +$396K 0.01% 953
2023
Q3 		$281K Buy
27,600
+7,500
+37% +$159K 0.01% 1275
2023
Q2 		$420K Buy
+20,100
New +$411K 0.01% 1178

Other funds holding SLRN

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Boothbay Fund Management's SLRN Position: Q1 2025 in Review

Boothbay Fund Management sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 29,828 shares — an estimated $93.7K sold.

Boothbay Fund Management first reported a position in SLRN in Q2 2023 and held it in 6 quarters. The position peaked at $2.46M in Q2 2023. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

  • Boothbay Fund Management reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 29,828 ACELYRIN shares in Q1 2025, an estimated $93.7K.
  • Boothbay Fund Management first reported a position in ACELYRIN in Q2 2023 and held it in 6 quarters.
  • Boothbay Fund Management's ACELYRIN position peaked at $2.46M in Q2 2023.
  • 105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.